| 18.22 2.54 (16.2%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.74  |
1-year : | 26.56 |
| Resists | First : | 19.47 |
Second : | 22.74 |
| Pivot price | 15.57 |
|||
| Supports | First : | 16.41 |
Second : | 14.52 |
| MAs | MA(5) : | 16.04 |
MA(20) : | 15.47 |
| MA(100) : | 16.1 |
MA(250) : | 15.81 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 79 |
D(3) : | 70 |
| RSI | RSI(14): 75.1 |
|||
| 52-week | High : | 20.04 | Low : | 11.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SIBN ] has closed above the upper band by 37.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 31.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.49 - 19.58 | 19.58 - 19.67 |
| Low: | 16.37 - 16.46 | 16.46 - 16.55 |
| Close: | 18.07 - 18.23 | 18.23 - 18.36 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Tue, 11 Nov 2025
SI-BONE Inc (SIBN) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Mon, 10 Nov 2025
Si-Bone: Q3 Earnings Snapshot - Stamford Advocate
Mon, 10 Nov 2025
Strong Q3 Results for SIBN Highlight Growing Demand and Profitab - GuruFocus
Mon, 10 Nov 2025
SI-BONE (SIBN) Boosts 2025 Revenue and Gross Margin Forecast - GuruFocus
Mon, 10 Nov 2025
SI-BONE, Inc. (SIBN) Q3 FY2025 earnings call transcript - Yahoo Finance
Mon, 10 Nov 2025
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 43 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 95.8 (%) |
| Shares Short | 2,660 (K) |
| Shares Short P.Month | 2,110 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.96 |
| Profit Margin | -12.9 % |
| Operating Margin | -14.4 % |
| Return on Assets (ttm) | -7.6 % |
| Return on Equity (ttm) | -14.2 % |
| Qtrly Rev. Growth | 21.7 % |
| Gross Profit (p.s.) | 3.41 |
| Sales Per Share | 4.29 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -31.97 |
| PEG Ratio | 0 |
| Price to Book value | 4.6 |
| Price to Sales | 4.24 |
| Price to Cash Flow | -241.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|